So that’s really the — that should be the market in the hospital setting. As you could imagine, it’s not easy to sell in the hospital in general. And so it’s actually — very, very proud of what the team has been able to accomplish. And stay tuned, I think, there’s more good news coming there. But again, it’s not a light switch that comes on, I think it’s gradually. And hopefully, there’s a light switch toward the next three to six months. But let’s see it and then we can discuss it with you guys.
Dipesh Patel: And my second question, what kind of infrastructure does Norgine plan to use to launch PEDMARQSI in Europe and what is the estimated size of the opportunity there?
Rosty Raykov: Adrian, over to you.
Adrian Haigh: They have a presence in all of the major European markets in Australia and New Zealand. They — I think, back of the envelope, they’re looking at allocating around 50 FTEs to the product and what I consider to be the appropriate level of commercial spend to make a success of the products. And they’re hiring a mixture of new specialist folks to fill gaps and also reallocating some people. But to be honest, that’s a very high level. It’s a question for Norgine really.
Rosty Raykov: And what I would also add because we got to — we’ve interacted with several teams in Europe overall. And I would say that what Norgine is really committed to pediatric oncology. Not only did they have our product but they have another product as well that they’re planning to launch roughly at the same time. It’s really exciting because their passionate and commitment is right up there with ours. I cannot be more pleased to see a very strong and capable player take on PEDMARQSI and really get access for it in these territories. So imagine that we’re going through 200 hospitals in the NCCN/COG setting, so imagine that with each country and each healthcare system, health economic argument, et cetera. So it’s a major, major task.
And they have done this many times and they’re up for it. And importantly, they’re really committed to this space. So this could not be a more perfect partner for PEDMARQSI. And in terms of the revenue expectations for the product, I would say that what we had modeled, as Adrian said earlier, is not that dissimilar to what they had modeled for it. So I think in terms of milestones and royalties, stay tuned to that. But most of the timing in these biotech deals, you have biobox, if you will, and people sort of discount those things heavily. Let’s give it a little bit of time but I think most of these things are very realistic.
Dipesh Patel: And then final question. Does Fennec plan to use any of the upfront cash from the Norgine transaction to expand its pipeline? If so, what kind of opportunities do you plan to pursue, whether it’s like development stage assets or approved products? And I think you kind of alluded to this, but I’ll ask you the question. Is it Fennec’s — is Fennec’s long term intent to remain focused on oncology?
Rosty Raykov: I think we just closed this deal. So the Board and management obviously has to evaluate everything from 360 degrees. We’ve always been a very, very good stewards of capital historically. I hope that to continue going forward. As you can imagine, the market is full with assets that need funding. And it’s something that we, as management and Board will have to decide at some stage, that’s what we want to pursue and we will obviously update the market on that. But for now, we’re keeping our heads down and we are executing on the opportunity ahead of us. I mean, as Adrian mentioned, from the number perspective, we have greater than 10 times the market opportunity in the community setting, and we’re really focused on that.
And what’s — again, what’s really, really exciting is that despite the J-Code issue, we’ve been able to put patients on drug and those patients have been reimbursable, right, which is really important. So then from here, let’s see what we can do in the coming months in terms of overall usage for the product, in addition to what’s coming up down the pipe with the pediatric hospitals, which, again, I discussed earlier from a P&T perspective.
Operator: And I’m showing no further questions at this time. I would now like to turn the conference back to Rosty for closing remarks.
Rosty Raykov: Thank you for the discussion, and good questions and joining us today. We look forward to updating you on our continued launch progress and corporate milestones on future quarterly calls. Thank you, and have a great day.
Operator: And this concludes today’s conference call. Thank you for participating. You may now disconnect.
